|
|
|
| Effects of Mouse Nerve Growth Factor Combined with Mecobalamin on Electromyography Serum Lipids and VitB12 Levels in Diabetic Peripheral Neuropathy |
| MENG Kaitao |
| The Affiliated Hospital of Jining Medical College, Shandong Jining 272029, China |
|
|
|
|
Abstract Objective: To investigate the effect of rat nerve growth factor combined with methylcobalamin in the treatment of diabetic peripheral neuropathy on patients with electromyography, blood lipids and VitB12 levels. Methods: The clinical data of 87 patients with diabetic peripheral neuropathy were selected for retrospective analysis. The selection time was from February 2018 to June 2020. According to different treatment methods, they were divided into control groups (treated with mecobalamin, n=43) and Observation group (treated with mouse nerve growth factor combined with mecobalamin, n=44), compare the two groups of common peroneal nerve (SNCV, MNCV), median nerve (SNCV, MNCV), TC, TG, HLD-L, LDL-C, NSE, VitB12 and TSS scores. Results: ①the two groups of common peroneal nerve (SNCV, MNCV), median nerve (SNCV, MNCV), TC, TG, LDL-C, NSE, VitB12, TSS score time effect, group effect and time and grouping There is a significant difference in the interaction of the two (P<0.05). ②there was no significant difference in the scores of common peroneal nerve (SNCV, MNCV), median nerve (SNCV, MNCV), TC, TG, LDL-C, NSE, VitB12, and TSS before treatment (P>0.05). After 2 weeks and 4 weeks of treatment, the common peroneal nerve (SNCV, MNCV), median nerve (SNCV, MNCV), and VitB12 of the observation group were higher than those of the control group, while the scores of TC, TG, LDL-C, NSE and TSS were lower Control group (P<0.05). ③TC, TG, LDL-C were positively correlated with the motor nerve conduction velocity of the common peroneal nerve and the median nerve, and the sensory nerve conduction velocity (P<0.05). Conclusion: The combination of mouse nerve growth factor and methylcobalamin in the treatment of DPN can not only improve nerve conduction velocity, but also reduce blood lipids and relieve clinical symptoms.
|
|
|
|
|
|
[1] 肖若然,娄锡恩.葛芪降糖方药联合甲钴胺治疗2型糖尿病周围神经病变(肾虚毒滞型)的临床观察[J].现代中医临床,2019,26(2):40~43.
[2] 刘辉,杜少辉.当归四逆汤联合鼠神经生长因子治疗糖尿病周围神经病变临床观察[J].西部中医药,2019,32(7):89~92.
[3] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中国实用内科杂志,2018,38(4):292~344.
[4] 张玉凤,杨佳.鼠神经生长因子联合甲钴胺对视神经炎病人视野缺损程度的影响[J].内蒙古医科大学学报,2019,41(1):51~55.
[5] Mai W,Wei A,Lin X,et al.Efficacy and safety of traditional Chinese medicine injection with mecobalamin in treating diabetic peripheral neuropathy:a protocol for systematic review and meta-analysis[J].Medicine,2021,100(1):23702.
[6] 尹行志.鼠神经生长因子治疗脑梗死的临床疗效评价及对血浆D-D TXB2 BNP的影响[J].河北医学,2019,25(2):215~219.
[7] 袁芳,李雪莲.鼠神经生长因子联合甲钴胺对视神经炎患者视力及视野缺损的影响[J].中国医药导刊,2020,22(2):96~99.
[8] 王佳,胡予,罗蔓,等.注射用鼠神经生长因子治疗老年糖尿病周围神经病变的疗效和安全性评估[J].老年医学与保健,2019,25(1):55~58,82.
[9] Impellizzeri D,Peritore AF,Cordaro M,et al.The neuroprotective effects of micronized PEA (PEA-m) formulation on diabetic peripheral neuropathy in mice[J].FASEB,2019,33(10):11364~11380.
[10] 王凯悦,张新媛,聂瑶,等.脂类代谢异常与糖尿病视网膜微血管病变及神经元退行性改变的相关性研究[J].中华眼科医学杂志(电子版),2020,10(4):212~218. |
|
|
|
2021, Vol. 27 
